- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01988857
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children
Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix™) in Healthy Vietnamese Children
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
A phase III, single-group, open-label study of GSK Biologicals' vaccine BoostrixTM administered as a booster vaccine dose in healthy Vietnamese children aged 6-10 years. A single booster dose of BoostrixTM will be administered at Visit 1 (Day 0) and subjects will be observed until Visit 2 (Day 30). Safety will be assessed in terms of solicited adverse events (during 4 days post vaccination), unsolicited adverse events (during 31 days post vaccination) and serious adverse event (during the trial period).
This protocol summary was updated following an administrative change of adding the EudraCT number to this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Hanoi, Vietnam, 084
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- A male or female between, and including, 6 and 10 years of age at the time of the vaccination.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- Written informed assent to be obtained from the subject in addition to the informed consent signed by the parent(s)/LAR(s), as required by local regulations.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Subjects who have previously completed their routine vaccinations against diphtheria, tetanus and pertussis diseases according to the local recommended vaccination schedule at that time and have not received the vaccine in the last two years prior to study dose administration.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced abstinence or adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. Inhaled and topical steroids are allowed.
- Administration of a vaccine not foreseen by the study protocol within 30 days prior to the booster vaccine dose, or planned administration during the study period.
- Administration of immunoglobulins and/or any blood products within the three months preceding Visit 1 or planned administration during the study period.
- Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- A history of previous or intercurrent diphtheria, tetanus or pertussis disease.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Major congenital defects or serious chronic illness.
- Acute disease and/or fever at the time of enrollment.
- Pregnant or lactating female.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: dTpa Group
|
Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Numbers of Subjects With Any and Grade 3 Solicited Local Symptoms
Zeitfenster: Within 4 days (Days 0-3) post vaccination period
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Relationship analysis was not performed.
|
Within 4 days (Days 0-3) post vaccination period
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Zeitfenster: Within 4 days (Days 0-3) post vaccination period
|
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 fever = fever > 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
Within 4 days (Days 0-3) post vaccination period
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Zeitfenster: Within 31 days (Days 0-30) post vaccination period
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 31 days (Days 0-30) post vaccination period
|
Number of Subjects With Serious Adverse Events (SAEs)
Zeitfenster: During the entire study period (From Day 0 to Day 30)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During the entire study period (From Day 0 to Day 30)
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 115739
- 2013-003859-37 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tetanus
-
Changchun BCHT Biotechnology Co.The First Affiliated Hospital of Yunnan University of Traditional Chinese... und andere MitarbeiterNoch keine Rekrutierung
-
ABO Holdings, Inc.Aktiv, nicht rekrutierendImpfung gegen Tetanus, Diphtherie und azelluläre PertussisVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenKeuchhusten | Tetanus | Diphtherie | Diphtherie-Immunisierung | Tetanus-Immunisierung | Clostridium difficile-ImmunisierungMali
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeRussische Föderation
-
GlaxoSmithKlineBeendetDiphtherie-Tetanus-azelluläre PertussisKolumbien
-
CanSino Biologics Inc.Aktiv, nicht rekrutierendDiphtherie, Tetanus und azelluläre KeuchhustenChina
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeKorea, Republik von
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenDiphtherie, Tetanus und KeuchhustenSpanien
-
GlaxoSmithKlineAbgeschlossenDiphtherie, Tetanus und Keuchhusten
-
Hospices Civils de LyonAbgeschlossen
Klinische Studien zur Boostrix™
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenBelgien
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre Keuchhusten | Diphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeAustralien
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenVereinigte Staaten
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeFinnland, Australien, Spanien, Italien, Kanada, Tschechien
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre Keuchhusten | Diphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeVereinigte Staaten
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenVereinigte Staaten
-
DBV TechnologiesUniversity Hospital, GenevaAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenMexiko, Chile
-
St. Justine's HospitalMinistere de la Sante et des Services SociauxAbgeschlossen
-
University of Prince Edward IslandThe Queen Elizabeth HospitalAbgeschlossen